Is right hemicolectomy ever necessary for low-grade and high-grade appendiceal mucinous neoplasm (LAMN and HAMN)? A systematic review of the literature.
메타분석
1/5 보강
[BACKGROUND] Low-grade and high-grade appendiceal mucinous neoplasms (LAMN and HAMN) are rare appendiceal tumours.
- 연구 설계 systematic review
APA
Bianco G, Staccini G, et al. (2026). Is right hemicolectomy ever necessary for low-grade and high-grade appendiceal mucinous neoplasm (LAMN and HAMN)? A systematic review of the literature.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(3), 111320. https://doi.org/10.1016/j.ejso.2025.111320
MLA
Bianco G, et al.. "Is right hemicolectomy ever necessary for low-grade and high-grade appendiceal mucinous neoplasm (LAMN and HAMN)? A systematic review of the literature.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 52, no. 3, 2026, pp. 111320.
PMID
41650662 ↗
Abstract 한글 요약
[BACKGROUND] Low-grade and high-grade appendiceal mucinous neoplasms (LAMN and HAMN) are rare appendiceal tumours. When confined to the appendix, their prognosis is generally favourable. However, there remains a potential risk of progression to pseudomyxoma peritonei (PMP) or distant metastases. Historically, this perceived risk has led to extensive surgical resections for non-disseminated cases, with right hemicolectomy (RHC) still frequently performed. Despite this, standardised guidelines remain limited and largely based on expert consensus rather than high-level evidence. This study aimed to evaluate the necessity of RHC in the management of non-disseminated LAMN and HAMN.
[METHODS] A comprehensive literature search was conducted across PubMed, Cochrane Library, Web of Science and Google Scholar to identify articles reporting cases of non-disseminated LAMN or HAMN treated with RHC and including histopathological assessment of lymph node status. Studies were excluded if they involved patients who did not undergo RHC, presented with PMP, included other tumour types or lacked lymph node data.
[RESULTS] Thirty articles published between 2009 and 2025 were included, comprising 306 LAMN and 31 HAMN cases treated with RHC. Follow-up period ranged from 1 to 146 months for LAMN and 4-171 months for HAMN. Across all studies, no lymph node metastases were identified on histopathological examination.
[CONCLUSIONS] This systematic review represents one of the largest analyses on non-disseminated LAMN and HAMN cases treated with RHC. The consistent absence of nodal involvement suggests that lymphadenectomy provides no oncological benefit, thereby questioning the necessity of completion surgery in these rare tumours.
[METHODS] A comprehensive literature search was conducted across PubMed, Cochrane Library, Web of Science and Google Scholar to identify articles reporting cases of non-disseminated LAMN or HAMN treated with RHC and including histopathological assessment of lymph node status. Studies were excluded if they involved patients who did not undergo RHC, presented with PMP, included other tumour types or lacked lymph node data.
[RESULTS] Thirty articles published between 2009 and 2025 were included, comprising 306 LAMN and 31 HAMN cases treated with RHC. Follow-up period ranged from 1 to 146 months for LAMN and 4-171 months for HAMN. Across all studies, no lymph node metastases were identified on histopathological examination.
[CONCLUSIONS] This systematic review represents one of the largest analyses on non-disseminated LAMN and HAMN cases treated with RHC. The consistent absence of nodal involvement suggests that lymphadenectomy provides no oncological benefit, thereby questioning the necessity of completion surgery in these rare tumours.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.